Dutch Bros Inc. (BROS) Stock Forecast
Data as of Oct 31, 2026Consumer Cyclical · Current price $42.70 (-2.91%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Brian Mullan | Piper Sandler | $59.00 | +38.2% |
| Mar 9, 2026 | Margaret-May Binshtok | Wolfe Research | $77.00 | +80.3% |
| Mar 2, 2026 | Christine Cho | Goldman Sachs | $75.00 | +75.6% |
| Feb 13, 2026 | Logan Reich | RBC Capital | $75.00 | +75.6% |
| Jan 7, 2026 | Jeffrey Bernstein | Bernstein | $76.00 | +78.0% |
| Dec 4, 2025 | Nick Setyan | Mizuho Securities | $80.00 | +87.4% |
| Nov 6, 2025 | Brian Harbour | Morgan Stanley | $84.00 | +96.7% |
| Oct 31, 2025 | Chris O'Cull | Stifel Nicolaus | $75.00 | +75.6% |
| Oct 28, 2025 | Dennis Geiger | UBS | $85.00 | +99.1% |
| Oct 27, 2025 | Logan Reich | RBC Capital | $85.00 | +99.1% |
| May 5, 2025 | Dennis Geiger | UBS | $80.00 | +87.4% |
| Apr 14, 2025 | Brian Harbour | Morgan Stanley | $80.00 | +87.4% |
| Jan 10, 2025 | Chris O'Cull | Stifel Nicolaus | $62.00 | +45.2% |
| Nov 11, 2024 | Brian Mullan | Piper Sandler | $51.00 | +19.4% |
| Aug 15, 2024 | Dennis Geiger | UBS | $39.00 | -8.7% |
| Aug 8, 2024 | Gregory Francfort | Guggenheim | $36.00 | -15.7% |
| Aug 8, 2024 | Chris O'Cull | Stifel Nicolaus | $38.00 | -11.0% |
| Mar 3, 2024 | Brian Mullan | Piper Sandler | $37.00 | -13.3% |
| Jan 15, 2024 | Chris O'Cull | Stifel Nicolaus | $35.00 | -18.0% |
| May 12, 2022 | Chris O`Cull | Stifel Nicolaus | $30.00 | -29.7% |
Top Analysts Covering BROS
BROS vs Sector & Market
| Metric | BROS | Consumer Cyclical Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.09 | 2.48 | 2.41 |
| Analyst Count | 32 | 12 | 19 |
| Target Upside | +59.6% | +248.0% | +21.5% |
| P/E Ratio | 66.72 | 16.33 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.02B | $2.05B | $2.07B | 18 |
| 2027-03-31 | $543M | $554M | $563M | 11 |
| 2027-06-30 | $624M | $637M | $647M | 7 |
| 2027-09-30 | $635M | $648M | $659M | 8 |
| 2027-12-31 | $655M | $669M | $679M | 7 |
| 2028-03-31 | $662M | $675M | $686M | 6 |
| 2028-06-30 | $758M | $774M | $786M | 6 |
| 2028-09-30 | $766M | $781M | $794M | 11 |
| 2028-12-31 | $785M | $801M | $814M | 6 |
| 2029-12-31 | $3.51B | $3.61B | $3.70B | 5 |
| 2030-12-31 | $4.07B | $4.19B | $4.29B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.82 | $0.88 | $0.95 | 13 |
| 2027-03-31 | $0.21 | $0.22 | $0.22 | 5 |
| 2027-06-30 | $0.36 | $0.37 | $0.38 | 5 |
| 2027-09-30 | $0.30 | $0.31 | $0.32 | 5 |
| 2027-12-31 | $0.28 | $0.28 | $0.29 | 5 |
| 2028-03-31 | $0.26 | $0.26 | $0.27 | 6 |
| 2028-06-30 | $0.43 | $0.45 | $0.45 | 6 |
| 2028-09-30 | $0.36 | $0.37 | $0.38 | 7 |
| 2028-12-31 | $0.32 | $0.33 | $0.34 | 9 |
| 2029-12-31 | $1.72 | $1.79 | $1.85 | 2 |
| 2030-12-31 | $2.18 | $2.26 | $2.33 | 2 |
Frequently Asked Questions
What is the analyst consensus for BROS?
The consensus among 32 analysts covering Dutch Bros Inc. (BROS) is Buy with an average price target of $73.58.
What is the highest price target for BROS?
The highest price target for BROS is $85.00, set by Dennis Geiger at UBS on 2025-10-28.
What is the lowest price target for BROS?
The lowest price target for BROS is $30.00, set by Chris O`Cull at Stifel Nicolaus on 2022-05-12.
How many analysts cover BROS?
32 analysts have issued ratings for Dutch Bros Inc. in the past 12 months.
Is BROS a buy or sell right now?
Based on 32 analyst ratings, BROS has a consensus rating of Buy (2.09/5) with a +59.6% upside to the consensus target of $73.58.
What are the earnings estimates for BROS?
Analysts estimate BROS will report EPS of $0.88 for the period ending 2026-12-31, with revenue estimated at $2.05B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.